CD19-IL7Ra CAR-T cells therapy (Chulalongkorn University)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameCD19-IL7Ra CAR-T cells therapy (Chulalongkorn University)

Drug Alias NameCMD63CMD-63

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsInterleukin-7 receptor subunit alpha modulators

TargetsB-lymphocyte antigen CD19Interleukin-7 receptor subunit alpha

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryThailand

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesChulalongkorn University

China Registration ClassN/A

Develop Information

Active CompaniesChulalongkorn University

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A